These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35780062)

  • 1. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
    Talleur AC; Myers R; Annesley C; Shalabi H
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
    Saifi O; Lester SC; Breen WG; Rule WG; Lin Y; Bennani NN; Rosenthal A; Munoz J; Murthy HS; Kharfan-Dabaja MA; Peterson JL; Hoppe BS
    Am J Hematol; 2024 Jan; 99(1):124-134. PubMed ID: 37950857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Cummins KD; Gill S
    Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
    Li X; Chen W
    Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
    Schroeder BA; Jess J; Sankaran H; Shah NN
    Curr Opin Hematol; 2022 Jul; 29(4):225-232. PubMed ID: 35787551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
    Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
    Front Immunol; 2021; 12():670286. PubMed ID: 34135898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
    Valand HA; Huda F; Tu RK
    AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
    Strati P; Gregory T; Majhail NS; Jain N
    JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.